首页> 美国卫生研究院文献>Cell Bioscience >MAP4K4: an emerging therapeutic target in cancer
【2h】

MAP4K4: an emerging therapeutic target in cancer

机译:MAP4K4:癌症的新兴治疗靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The serine/threonine kinase MAP4K4 is a member of the Ste20p (sterile 20 protein) family. MAP4K4 was initially discovered in 1995 as a key kinase in the mating pathway in Saccharomyces cerevisiae and was later found to be involved in many aspects of cell functions and many biological and pathological processes. The role of MAP4K4 in immunity, inflammation, metabolic and cardiovascular disease has been recognized. Information regarding MAP4K4 in cancers is extremely limited, but increasing evidence suggests that MAP4K4 also plays an important role in cancer and MAP4K4 may represent a novel actionable cancer therapeutic target. This review summarizes our current understanding of MAP4K4 regulation and MAP4K4 in cancer. MAP4K4-specific inhibitors have been recently developed. We hope that this review article would advocate more basic and preclinical research on MAP4K4 in cancer, which could ultimately provide biological and mechanistic justifications for preclinical and clinical test of MAP4K4 inhibitor in cancer patients.
机译:丝氨酸/苏氨酸激酶MAP4K4是Ste20p(无菌20蛋白)家族的成员。 MAP4K4最初于1995年被发现为酿酒酵母交配途径中的关键激酶,后来被发现涉及细胞功能的许多方面以及许多生物学和病理学过程。已经认识到MAP4K4在免疫,炎症,代谢和心血管疾病中的作用。有关癌症中MAP4K4的信息极为有限,但越来越多的证据表明MAP4K4在癌症中也起着重要作用,而MAP4K4可能代表了一种新型的可治疗癌症治疗靶标。这篇综述总结了我们目前对癌症中MAP4K4调控和MAP4K4的理解。最近已经开发了MAP4K4特异性抑制剂。我们希望这篇综述文章能够提倡对MAP4K4在癌症中进行更多的基础和临床前研究,从而最终为癌症患者中MAP4K4抑制剂的临床前和临床试验提供生物学和力学依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号